Genmab and Seagen submit cancer drug application to US FDA

The US FDA will evaluate a cervical cancer treatment developed by Genmab and Seagen
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Danish biotech firm Genmab and US biotech firm Seagen have applied for an accelerated approval of the drug candidate tisotumab vedotin at the US Food and Drug Administration, according to a Genmab press release on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading